Bionano Genomics (BNGO) vs Nautilus Biotechnology (NAUT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Nautilus Biotechnology (NAUT) has outperformed Bionano Genomics (BNGO) over the past year, gaining 101.8% versus a loss of 26.3%. Over five years, NAUT leads with a -68.1% price change compared with -100.0% for BNGO. Nautilus Biotechnology is the larger company by market cap ($253.2 million vs $17.4 million), about 14.5 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BNGO | NAUT |
|---|---|---|
| Share price | $1.48 | $1.99 |
| Market cap | $17.43M | $253.24M |
| 1-day change | +1.37% | +9.34% |
| YTD return | -4.58% | -6.67% |
| 1-year return | -26.26% | +101.77% |
| 5-year return | -99.95% | -68.13% |
| EPS (TTM) | $-3.02 | $-0.45 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.23 | $4.31 |
| 52-week low | $1.00 | $0.82 |
| Distance from 52-week high | -33.63% | -53.83% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +237.84% | +92.46% |
| Average volume | 921.59K | 2.66M |
| Shares outstanding | 11.78M | 127.26M |
| Employees | 95 | 127 |
| Sector | Industrials | Industrials |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Laboratory Analytical Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Nautilus Biotechnology is about 14.5 times larger than Bionano Genomics by market value ($253.24M vs $17.43M).
- NAUT has outperformed BNGO by 128.0 percentage points over the past year.
About Bionano Genomics
BNGO stock →Bionano Genomics, Inc., together with its subsidiaries, provides genome analysis solutions in the Americas, Europe, the Middle East, Africa, China, Japan, South Korea, Singapore, India, and Australia. The company offers genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants.
Industrials · Biotechnology: Laboratory Analytical Instruments · 95 employees
About Nautilus Biotechnology
NAUT stock →Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome in the United States. The company develops Nautilus Voyager Platform, which includes an end-to-end solution comprising instruments, reagents, consumables, and software analysis.
Industrials · Biotechnology: Laboratory Analytical Instruments · 127 employees
BNGO vs NAUT FAQ
Which is bigger, Bionano Genomics or Nautilus Biotechnology?
Nautilus Biotechnology (NAUT) is larger, with a market capitalization of $253.24M compared with $17.43M for Bionano Genomics (BNGO).
Which stock has performed better over the past year, BNGO or NAUT?
NAUT returned +101.77% over the past 12 months, compared with -26.26% for BNGO (price return, excluding dividends). Past performance does not predict future results.
Are Bionano Genomics and Nautilus Biotechnology in the same industry?
Yes. Both are classified in the Biotechnology: Laboratory Analytical Instruments industry within the Industrials sector.